-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Equal-Weight on Summit Therapeutics, Raises Price Target to $20

Benzinga·10/01/2026 12:55:02
Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Equal-Weight and raises the price target from $18 to $20.